Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Practice Guideline
. 2025 Sep;39(9):1537-1566.
doi: 10.1111/jdv.20639. Epub 2025 May 2.

European Guideline (EuroGuiDerm) on atopic eczema: Living update

Affiliations
Practice Guideline

European Guideline (EuroGuiDerm) on atopic eczema: Living update

A Wollenberg et al. J Eur Acad Dermatol Venereol. 2025 Sep.

Abstract

The evidence- and consensus-based living guideline on atopic eczema was developed in accordance with the EuroGuiDerm Guideline and Consensus Statement Development Manual. The original EuroGuiDerm Guideline on atopic eczema was published in June 2022. Since then, the part of the guideline dealing with systemic therapy has been updated twice. This paper summarizes the results of the second update. Twenty-eight experts (including clinicians and patient representatives) from 12 European countries participated. The updated guideline provides guidance on which patients should be treated with systemic therapies, as well as recommendations and detailed information on each systemic drug. The systemic treatment options discussed in the guideline comprise conventional immunosuppressive drugs (azathioprine, ciclosporin, glucocorticosteroids, methotrexate and mycophenolate mofetil), biologics (dupilumab, lebrikizumab, nemolizumab and tralokinumab) and Janus kinase (JAK) inhibitors (abrocitinib, baricitinib and upadacitinib). Additionally, the updated guidelines address considerations for paediatric, adolescent, pregnant and breastfeeding patients. For all other aspects, please refer to the 2022 version.

PubMed Disclaimer

Conflict of interest statement

This is a summary of the second update of the EuroGuiDerm Guideline on atopic eczema. For the complete guideline, methods report (including COI disclosures) and evidence report, see https://www.guidelines.edf.one/.

Figures

FIGURE 1
FIGURE 1
Stepped‐care plan for adults with atopic eczema.
FIGURE 2
FIGURE 2
Stepped‐care plan for children and adolescents with atopic eczema.

References

    1. Kaminski‐Hartenthaler A, Meerpohl JJ, Gartlehner G, Kien C, Langer G, Wipplinger J, et al. GRADE guidelines: 14. Going from evidence to recommendations: the significance and presentation of recommendations [GRADE Leitlinien: 14. Von der Evidenz zur Empfehlung: Die Bedeutung und Darstellung von Empfehlungen]. Z Evid Fortbild Qual Gesundhwes. 2014;108(7):413–420. - PubMed
    1. Drucker AM, Lam M, Prieto‐Merino D, Malek R, Ellis AG, Yiu ZZN, et al. Systemic immunomodulatory treatments for atopic dermatitis: living systematic review and network meta‐analysis update. JAMA Dermatol. 2024;160(9):936–944. - PMC - PubMed
    1. Drucker AM, Flohr C, Ellis AG, Prieto‐Merino D, Rochwerg B, Bohdanowicz M, et al. Systemic immunomodulatory treatments for atopic dermatitis: a living systematic review and network meta‐analysis. 2024. Available from: https://eczematherapies.com/research/. Accessed 18 July 2024.
    1. Silverberg JI, Simpson EL, Armstrong AW, de Bruin‐Weller MS, Irvine AD, Reich K. Expert perspectives on key parameters that impact interpretation of randomized clinical trials in moderate‐to‐severe atopic dermatitis. Am J Clin Dermatol. 2021;23(1):1–11. - PMC - PubMed
    1. Wollenberg A, Christen‐Zäch S, Taieb A, Paul C, Thyssen JP, de Bruin‐Weller M, et al. ETFAD/EADV eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children. J Eur Acad Dermatol Venereol. 2020;34(12):2717–2744. - PubMed

Publication types